SIREN : 382601227
PHARM ADIS is a French company founded 34 years ago, specialized in the sector Activités de conditionnement. Based in CEBAZAT (63118), this company of category ETI shows in 2024 a revenue of 5.0 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-02
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2024 | 2023 | 2022 | 2021 | 2020 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 4 983 441 € | 5 335 843 € | 4 706 215 € | 4 792 176 € | 5 106 702 € | 3 999 121 € | 4 421 114 € | 3 830 749 € |
| Net income | -281 914 € | -135 772 € | 27 452 € | 209 359 € | 228 496 € | 64 697 € | 232 814 € | 175 958 € |
| EBITDA | -215 292 € | 210 313 € | 234 369 € | 482 303 € | 854 998 € | 157 003 € | 445 980 € | 347 515 € |
| Net margin | -5.7% | -2.5% | 0.6% | 4.4% | 4.5% | 1.6% | 5.3% | 4.6% |
In 2024, PHARM ADIS achieves revenue of 5.0 M€. Revenue is growing positively over 8 years (CAGR: +3.3%). Slight decline of -7% vs 2023. After deducting consumption (748 k€), gross margin stands at 4.2 M€, i.e. a rate of 85%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches -215 k€, representing -4.3% of revenue. Warning negative scissor effect: despite revenue change (-7%), EBITDA varies by -202%, reducing margin by 8.3 pts. This reflects costs rising faster than revenue. Negative EBITDA means operations do not cover current expenses: concerning situation. Net income is negative at -282 k€ (-5.7% of revenue), which will impact equity.
4 983 441 €
4 235 538 €
-215 292 €
-342 245 €
-281 914 €
-4.3%
The debt ratio (= Financial debt / Equity x 100) stands at 288%. Critical situation: debt significantly exceeds equity, severely limiting borrowing capacity and exposing the company to default risk. Financial autonomy (= Equity / Total assets x 100) reaches 23%. The balance between equity and debt is satisfactory.
288.21%
22.8%
-6.698%
-19.285
71.9%
In 2024, the debt ratio of PHARM ADIS (288.21) ranks in the top 25% of the sector. This ratio measures the weight of debt relative to equity. A high ratio may indicate excessive dependence on external financing.
In 2024, the financial autonomy of PHARM ADIS (22.8%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.
In 2024, the repayment capacity of PHARM ADIS (-19.29) ranks in the bottom 25% of the sector, which is positive. This ratio indicates the number of years needed to repay debt with cash flow. A short capacity reflects controlled debt and good cash generation.
The liquidity ratio (= Current assets / Current liabilities) stands at 239.76. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
239.761
-37.669
In 2024, the liquidity ratio of PHARM ADIS (239.76) ranks above the median of the sector. This ratio measures the ability to cover short-term debt with current assets. This comfortable position offers an appreciable safety margin.
In 2024, the interest coverage of PHARM ADIS (-37.7x) ranks in the bottom 25% of the sector. This ratio indicates how many times operating income covers interest expenses. Low coverage may indicate fragility to rate or income variations.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 63 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 54 days. The company must finance 9 days of gap between collections and payments. Inventory turnover is 38 days (= Average inventory / Cost of goods x 360). Fast turnover, sign of good inventory management. Overall, WCR represents 100 days of revenue, i.e. 1.4 M€ to permanently finance. Over 2016-2024, WCR increased by +59%, requiring additional financing.
1 388 287 €
63 j
54 j
38 j
100 j
Based on 158 transactions of similar company sales (all years), the value of PHARM ADIS is estimated at 1 776 049 € (range 928 328€ - 3 328 306€). The price/revenue ratio is 0.36x (conservative valuation). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Only this financial indicator is available for this company.
This estimate is based on the analysis of 158 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare PHARM ADIS with other companies in the same sector:
Voir toutes les statistiques du secteur Activités de conditionnement
The revenue of PHARM ADIS in 2024 is 5.0 M€.
PHARM ADIS recorded a net loss in 2024.
The headquarters of PHARM ADIS is located in CEBAZAT (63118), in the department Puy-de-Dome.
The tax return of PHARM ADIS is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
PHARM ADIS operates in the sector Activités de conditionnement (NAF code 82.92Z). See the 'Sector positioning' section above to compare the company with its competitors.